Cancer Chemotherapy and Pharmacology

, Volume 5, Issue 4, pp 243–249 | Cite as

A pharmacokinetic simulation model for chemotherapy of brain tumor with an antitumor protein antibiotic, neocarzinostatin

Theoretical considerations behind a two-compartment model for continuous infusion via an internal carotid artery
  • Hiroshi Maeda
  • Yoshinori Sano
  • Jiro Takeshita
  • Zenta Iwai
  • Hideyuki Kosaka
  • Tohru Marubayashi
  • Yasuhiko Matsukado
Original Articles Neocarzinostatin Brain Tumor Pharmacokinetic


A pharmacokinetic two-compartment model for the treatment of brain tumors in man was simulated with the aid of a computer. The parameters necessary for the simulations such as inactivation rate constant, elimination rate constant, distribution volume, blood volume, cerebral blood flow, and cytotoxic drug concentration were either determined in this study or obtained from the literature. A proteinaceous antitumor antibiotic, neocarzinostatin (NCS), was utilized as a prototype drug because it has features making it advantageous in the treatment of brain tumor. In particular, NCS has an extremely short half-life in serum (t1/2≤3s), while it is relatively stable in the cerebrospinal fluid (CSF) (t1/2∼50s). Therefore, the drug level in the cerebral compartment can be made adequately high with an appropriate infusion velocity into the cerebral compartment; however, it was possible to keep the plasma level of the drug much lower than the toxic level. Thus, few side-effects should result. In an in vitro study, NCS was found to exhibit its cytotoxicity to glioblastoma cells at a concentration as low as 0.005 μg/ml. In contrast, the cytotoxicity was not apparent for the normal glia cells at 0.1 μg/ml. The model being considered in this investigation is a two-compartment model, which consists of the cerebral compartment and the rest of the circulatory system of the body. In this case the drug is infused via an internal carotid artery. The results of pharmacokinetic simulation and dose regimens for NCS are presented, based on the effective concentration of the drug to glioblastoma cells in culture and the available pharmacological parameters.


Brain Tumor Cerebral Blood Flow Internal Carotid Artery Glioblastoma Cell Elimination Rate Constant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Davson H (1967) Physiology of the cerebrospinal fluid. Churchill, London, p 55Google Scholar
  2. 2.
    Ebina T, Ohtsuki K, Seto M, Ishida N (1975) Specific G-2 block in HeLa-S3 cells by neocarzinostatin. Eur J Cancer 11:155Google Scholar
  3. 3.
    Fingl E, Woodbury DM (1975) Pharmacokinetics, general principle. In: Goodman LS, Gilman A (eds) The pharmacological basis of therapeutics, 5th edn. MacMillan, New York, p 1Google Scholar
  4. 4.
    Gibaldi M, Perrier D (1975) Pharmacokinetics. Marcel Dekker, New YorkGoogle Scholar
  5. 5.
    Ishida N, Miyazaki K, Kumagai K, Rikimaru M (1965) Neocarzinostatin, an antitumor antibiotic of high molecular weight. Isolation, physicochemical properties, and biological activities. J Antibiot (Tokyo) Ser A, 18:68Google Scholar
  6. 6.
    Ishida R, Takahashi T (1976) In vitro release of thymine from DNA by neocarzinostatin. Biochem Biophys Res Commun 68:256Google Scholar
  7. 7.
    Kappen LS, Goldberg IH (1978) Gaps in DNA induced by neocarzinostatin bear 3′- and 5′-phosphoryl termini. Biochemistry 17:729Google Scholar
  8. 8.
    Kumagai K, Ono Y, Nishikawa T, Ishida N (1966) Cytological studies on the effect of neocarzinostatin on HeLa cells. J Antibiot 19:69Google Scholar
  9. 9.
    Levin VA (1976) Pharmacological principles of brain tumor chemotherapy. In: Thompson RA, Gree JR (eds) Neoplasia in the central nervous system. Raven Press, New York, p 315Google Scholar
  10. 10.
    Maeda H, Matsumoto M (1979) Cytotoxic efffect of neocarzinostatin on human lymphoid cells. Tohoku J Exp Med 128:313Google Scholar
  11. 11.
    Maeda H, Kumagai K, Ishida N (1966) Characterization of neocarzinostatin. J Antibiot (Tokyo) 19:253Google Scholar
  12. 12.
    Maeda H, Glaser CB, Kuromizu K, Meienhofer J (1974) Structure of the antitumor protein neocarzinostatin. Amino acid sequence. Arch Biochem Biophys 164:379Google Scholar
  13. 13.
    Maeda H, Yamamoto N, Yamashita A (1976). Fate and distribution of [14C]succinyl neocarzinostatin in rats. Eur J Cancer 12:865Google Scholar
  14. 14.
    Maeda H, Sakamoto S, Ogata J (1977) Mechanism of accumulation of antitumor protein antibiotic neocarzinostatin in bladder tissue, intravenous administration, urinary excretion, and absorption into bladder tissue. Antimicrob Agents Chemother 11:941Google Scholar
  15. 15.
    Maeda H, Takeshita J, Iwai Z, Yamanami Y, Sakamoto S (1979) Computer simulation of a single-compartment model for a complete remission of leukemia with neocarzinostatin. Cancer and Chemotherapy 3:19 (in Japanese)Google Scholar
  16. 16.
    Maeda H, Takeshita J, Yamashita A (1980) Lymphotropic accumulation of an antitumor antibiotic protein, neocarzinostatin. Eur J Cancer 16:723Google Scholar
  17. 17.
    Marubayashi T, Sano Y, Matsukado Y, Maeda H, Iwai Z (1979) Chemotherapy of brain tumor based on pharmacokinetic model. II. Clinical effect of arterial infusion of neocarzinostatin via internal carotid artery. J Jpn soc Cancer Ther 19:312Google Scholar
  18. 18.
    Meyer JS, Gotoh F, Akiyama M, Yoshitake S (1967) Automatic recording of cerebral blood flow by nitrous oxide inhalation without blood loss. Neurology 17:838Google Scholar
  19. 19.
    Ono Y, Watanabe Y, Ishida N (1966) Mode of action of neocarzinostatin: Inhibition of DNA synthesis and degradation of DNA in Sarcina lutea. Biochim Biophys Acta 119:46Google Scholar
  20. 20.
    Sakamoto S, Maeda H, Ogata J (1979) Intracellular uptake of FITC-labeled neocarzinostatin into normal and cancer cells. Experientia 35:1233Google Scholar
  21. 21.
    Takeshita J, Maeda H, Koike K (1980) Subcellular site of action of neocarzinostatin: Intracellular incorporation, DNA breakdown and cytotoxicity. J Biochem 88:1071Google Scholar
  22. 22.
    Toby RA (1975) Different drugs arrest cells at a numbers of distinct stages in G-2. Nature 254:245Google Scholar

Copyright information

© Springer-Verlag 1981

Authors and Affiliations

  • Hiroshi Maeda
    • 1
  • Yoshinori Sano
    • 2
  • Jiro Takeshita
    • 1
  • Zenta Iwai
    • 3
  • Hideyuki Kosaka
    • 2
  • Tohru Marubayashi
    • 2
  • Yasuhiko Matsukado
    • 2
  1. 1.Department of MicrobiologyKumamoto University School of MedicineKumamotoJapan
  2. 2.Department of NeurosurgeryKumamoto University School of MedicineKumamotoJapan
  3. 3.Department of Mechanical Engineering, Faculty of EngineeringKumamoto UniversityKumamotoJapan

Personalised recommendations